Product logins

Find logins to all Clarivate products below.


: Drugs to Watch

Here you will find relevant articles and insight into all Clarivate related products and news.

Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022 Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Blog June 23, 2022
Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Clinical research Clinical trials Drugs to Watch
Expected blockbusters: A year in progress Expected blockbusters: A year in progress
Blog November 18, 2019
Expected blockbusters: A year in progress
Drugs to Watch
Potential blockbusters make a splash on market entry Potential blockbusters make a splash on market entry
Blog June 13, 2019
Potential blockbusters make a splash on market entry
blockbuster Cortellis Cortellis Analytics
Blog March 20, 2019
Immune-related and genetic disorder products drive Cortellis Drugs to Watch 2019
autoimmunity Blockbusters Breakthrough Therapy
Blog October 31, 2018
Indivior’s Sublocade contributing to transformation of opioid dependence market
Blockbuster drugs buprenorphine Cortellis
Blog October 18, 2018
Roche’s Hemlibra: Market expansion approved, but safety an initial concern?
Drugs to Watch
Blog October 3, 2018
Erleada gains first-mover advantage in CRPC
apalutamide Blockbuster drugs Cortellis
Blog September 19, 2018
Shire’s Takhzyro expected to dominate in hereditary angioedema
Drugs to Watch Portfolio strategy Rare diseases

Drugs to Watch

Potential blockbusters make a splash on market entry Potential blockbusters make a splash on market entry
Blog June 13, 2019
Potential blockbusters make a splash on market entry
Blog March 20, 2019
Immune-related and genetic disorder products drive Cortellis Drugs to Watch 2019
Blog October 31, 2018
Indivior’s Sublocade contributing to transformation of opioid dependence market
Blog October 3, 2018
Erleada gains first-mover advantage in CRPC
Blog August 29, 2018
First-ever RNAi drug Onpattro (patisiran) approved in U.S. for hereditary transthyretin-mediated amyloidosis
Blog August 15, 2018
Biktarvy poised to help Gilead recapture share in the HIV market
Blog August 1, 2018
GW’s Epidiolex becomes the first cannabinoid-based drug approved for epilepsy
Blog June 28, 2018
ASCO 2018: paradigm changers and emerging blockbusters
Blog May 23, 2018
FDA approval of first-in-class Aimovig set to transform the migraine market
Blog March 22, 2018
Record number of blockbusters forecast for 2018 launch as the pace of pharmaceutical innovation accelerates